Sucampo Pharmaceuticals, Inc.
SCMP
SCMP was delisted on the 12th of February, 2018.
3 hedge funds and large institutions have $21K invested in Sucampo Pharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 183 closing their positions.
98% less funds holding
Funds holding: 188 → 3 (-185)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $645M → $21K (-$645M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 183
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$73.1M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
-$44.4M |
| 3 |
Renaissance Technologies
New York
|
-$35.1M |
| 4 |
PC
Paulson & Co
New York
|
-$28.7M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$27.8M |
SCMP Hedge Fund Activity: Q1 2018 in Review
3 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Sucampo Pharmaceuticals, Inc. (SCMP) for Q1 2018, worth a combined $21K — down 100% from $645M a quarter earlier.
Sellers outnumbered buyers: 183 funds closed out of SCMP and 0 opened new positions — a net loss of 183 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $73.1M sold.
- 3 institutional investors held Sucampo Pharmaceuticals, Inc. (SCMP) as of Q1 2018, down from 188 in Q4 2017.
- Funds reported $21K of Sucampo Pharmaceuticals, Inc. stock for Q1 2018, down 100% quarter-over-quarter.
- 0 funds opened new Sucampo Pharmaceuticals, Inc. positions in Q1 2018 and 183 closed out, a net change of -183 holders.
- The largest Sucampo Pharmaceuticals, Inc. seller in Q1 2018 was BlackRock, an estimated $73.1M sold.
Based on aggregated 13F filings for Q1 2018.